UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2020.
Commission File Number001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrant’s name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form 20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
On February 6, 2020, Summit Therapeutics plc (the “Company”) announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (“Eurofarma”). A $1.0 million milestone payment was triggered by the Company achieving its initial patient enrollment target at its trial sites in Latin America for the Phase 3 clinical trials of ridinilazole forC. difficile infection. The related press release is attached hereto as Exhibit 99.1.
This Report on Form6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on FormF-3 (FileNo. 333-232074).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC | ||||||
Date: February 6, 2020 | By: | /s/ Glyn Edwards | ||||
Glyn Edwards | ||||||
Chief Executive Officer |